Table 3 Antihypertensive drug treatment during Syst-Eur 2
Formerly randomised to placebo | Formerly randomised to active treatment | |||||||
|---|---|---|---|---|---|---|---|---|
Month 3 | Year 1 | Year 3 | Last visit | Month 3 | Year 1 | Year 3 | Last visit | |
Total number of patients | 1086 | 1561 | 1210 | 1691 | 1206 | 1682 | 1291 | 1825 |
On AH drugs | 966 (89%) | 1504 (96%) | 1177 (97%) | 1605 (95%) | 1186 (98%) | 1654 (98%) | 1267 (98%) | 1762 (97%) |
Only nitrendipine | 713 (66%) | 732 (47%) | 403 (33%) | 596 (35%) | 651 (54%) | 747 (44%) | 475 (37%) | 676 (37%) |
Study drugs other than nitrendipine | 127 (12%) | 547 (35%) | 546 (45%) | 687 (41%) | 466 (39%) | 738 (44%) | 599 (46%) | 799 (44%) |
(no other AH drugs) | ||||||||
Study drugs + other AH drugs | 19 (2%) | 82 (5%) | 118 (10%) | 145 (9%) | 14 (1%) | 69 (4%) | 120 (9%) | 155 (8%) |
Other AH drugs only | 107 (10%) | 143 (9%) | 110 (9%) | 177 (10%) | 55 (5%) | 100 (6%) | 73 (5%) | 132 (7%) |
Drugs taken† | ||||||||
Nitrendipine | 821 (76%) | 1186 (76%) | 883 (73%) | 1194 (71%) | 998 (83%) | 1322 (79%) | 974 (75%) | 1328 (73%) |
Enalapril | 132 (12%) | 552 (35%) | 565 (47%) | 693 (41%) | 426 (35%) | 714 (42%) | 618 (48%) | 823 (45%) |
Hydrochlorothiazide | 22 (2%) | 157 (10%) | 272 (22%) | 326 (19%) | 168 (14%) | 335 (20%) | 334 (26%) | 424 (23%) |
Other AH drugs | 126 (12%) | 225 (14%) | 228 (19%) | 322 (19%) | 69 (6%) | 169 (10%) | 193 (15%) | 287 (16%) |
No AH drugs | 120 (11%) | 57 (4%) | 33 (3%) | 79 (5%) | 20 (2%) | 28 (2%) | 24 (2%) | 58 (3%) |
Treatment unknown | NA | NA | NA | 7 (0%) | NA | NA | NA | 5 (0%) |